Neurocrine Biosciences' (NBIX) "Hold" Rating Reiterated at Needham & Company LLC

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report)'s stock had its "hold" rating reissued by analysts at Needham & Company LLC in a note issued to investors on Tuesday, Benzinga reports.

Other equities analysts also recently issued research reports about the company. Barclays increased their price target on Neurocrine Biosciences from $145.00 to $150.00 and gave the company an "overweight" rating in a report on Tuesday, January 23rd. Mizuho increased their price target on Neurocrine Biosciences from $116.00 to $140.00 and gave the company a "neutral" rating in a report on Thursday, February 8th. Citigroup lowered their price target on Neurocrine Biosciences from $141.00 to $140.00 and set a "neutral" rating on the stock in a report on Thursday, February 8th. StockNews.com upgraded Neurocrine Biosciences from a "buy" rating to a "strong-buy" rating in a report on Thursday, February 8th. Finally, Wedbush reiterated an "outperform" rating and set a $147.00 price target on shares of Neurocrine Biosciences in a report on Wednesday, April 17th. Seven analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $139.67.

Neurocrine Biosciences Stock Performance

Shares of NASDAQ NBIX traded up $6.43 during mid-day trading on Tuesday, reaching $140.09. The company had a trading volume of 1,607,701 shares, compared to its average volume of 849,997. The stock has a fifty day moving average of $136.21 and a two-hundred day moving average of $127.35. The company has a market capitalization of $13.94 billion, a price-to-earnings ratio of 55.23 and a beta of 0.25. Neurocrine Biosciences has a 12-month low of $89.04 and a 12-month high of $148.37.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last released its quarterly earnings data on Wednesday, February 7th. The company reported $1.44 EPS for the quarter, topping analysts' consensus estimates of $1.13 by $0.31. Neurocrine Biosciences had a return on equity of 12.85% and a net margin of 13.23%. The firm had revenue of $515.20 million for the quarter, compared to the consensus estimate of $518.52 million. During the same quarter in the prior year, the company posted $0.88 earnings per share. The firm's revenue was up 25.0% on a year-over-year basis. Sell-side analysts forecast that Neurocrine Biosciences will post 4.84 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Neurocrine Biosciences news, Director Richard F. Pops sold 15,000 shares of Neurocrine Biosciences stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $132.47, for a total transaction of $1,987,050.00. Following the completion of the transaction, the director now directly owns 29,512 shares of the company's stock, valued at $3,909,454.64. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Neurocrine Biosciences news, CFO Matt Abernethy sold 1,352 shares of Neurocrine Biosciences stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $132.85, for a total transaction of $179,613.20. Following the completion of the transaction, the chief financial officer now directly owns 31,528 shares of the company's stock, valued at $4,188,494.80. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Richard F. Pops sold 15,000 shares of Neurocrine Biosciences stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $132.47, for a total value of $1,987,050.00. Following the transaction, the director now directly owns 29,512 shares of the company's stock, valued at $3,909,454.64. The disclosure for this sale can be found here. Insiders sold a total of 186,994 shares of company stock valued at $25,806,409 over the last ninety days. 4.60% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. CWM LLC raised its holdings in shares of Neurocrine Biosciences by 47.9% in the third quarter. CWM LLC now owns 2,049 shares of the company's stock valued at $231,000 after buying an additional 664 shares during the last quarter. AE Wealth Management LLC bought a new position in shares of Neurocrine Biosciences in the third quarter valued at about $521,000. SG Americas Securities LLC bought a new position in shares of Neurocrine Biosciences in the third quarter valued at about $2,751,000. Avior Wealth Management LLC raised its holdings in shares of Neurocrine Biosciences by 74.4% in the third quarter. Avior Wealth Management LLC now owns 4,509 shares of the company's stock valued at $507,000 after buying an additional 1,924 shares during the last quarter. Finally, Mach 1 Financial Group LLC bought a new position in shares of Neurocrine Biosciences in the third quarter valued at about $496,000. 92.59% of the stock is owned by institutional investors.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.